Biotek-snakken — Maj 2024
-
ASCELIA PHARMA SUCCESSFULLY MEETS PRIMARY ENDPOINT WITH STRONG HEADLINE RESULTS IN ORVIGLANCE PHASE 3 STUDY
-
Kort-video: Stenocare, som er markedsleder inden for medicinsk cannabis, har igen et kvartal med stigende omsætning og faldende omkostninger. Selskabet har fået endnu et produkt godkendt i Danmark og i Australien og er godt på vej til at nå målsætningen om at fordoble omsætningen i 2024. Hør mere i denne video, hvor Helge Larsen taler med CEO Thomas Skovlund Schnegelsberg. https://www.proinvestor.com/boards/120262/
-
Calliditas Therapeutics. Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon
for the Treatment for Primary IgA Nephropathy in Adult Patients -
Godmorgen
-
Da ingen andre har nævnt det - per d.d.: Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib;
-
-
Calliditas ahead of Q1: Patient enrollment is the lead indicaton at this stage
(RESEARCH UPDATE 2024-05-06)
"Our base case valuation is SEK 270 (270), a Bull Case of SEK 390 (390) and a Bear Case of SEK 70 (70)."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind